NuvaRing Lawsuit 2026: Settlements, Payouts, Claims

Never Miss a Lawsuit Update

Mark Lawfold as a Preferred Source so you never miss a settlement deadline or new filing.

The NuvaRing lawsuit refers to thousands of legal claims filed against Merck & Co by women who suffered blood clots, strokes, and other life-threatening injuries after using the hormonal contraceptive ring. Merck agreed to a $100 million settlement in 2014, but questions about new claims continue into 2026.

That settlement covered roughly 3,800 cases. Thousands of women used NuvaRing and never filed.

This article breaks down where the litigation stands right now, what the original settlement paid out, which injuries qualify, and whether filing a new lawsuit is still possible. One fact that might surprise you: studies showed NuvaRing users faced a 56% higher risk of blood clots compared to women using older birth control pills.

This is also helpful — Science Lawsuit Palestinian Territory 2026: Full Case Guide

If you or someone you know was harmed by this device, the information here will help you figure out your next step.

NuvaRing Lawsuit 2026

The NuvaRing lawsuit in 2026 is largely in its post-settlement phase. The major wave of litigation that began around 2008 resulted in a global settlement in February 2014. No active multidistrict litigation remains on the federal docket.

That said, individual lawsuits can still surface. Women who only recently discovered their injuries were linked to NuvaRing may have legal options depending on their state’s discovery rule.

The bulk of litigation is over. But “over” doesn’t mean every door is shut. State-level statutes and discovery rules create narrow windows that some claimants might still use.

New cases in 2026 would likely be filed individually, not as part of any consolidated proceeding. Any woman considering action should act fast, because even the most generous filing deadlines are running out.

NuvaRing Lawsuit Update

The latest NuvaRing lawsuit update confirms no new mass litigation has been filed as of early 2026. The MDL was effectively resolved after Merck’s settlement, and no new federal consolidation has been requested.

One development worth tracking: Organon & Co took over manufacturing NuvaRing when Merck spun off its women’s health division in June 2021. Any future product liability claims related to NuvaRing manufactured after that date would name Organon, not Merck.

The FDA has not issued any new safety warnings about NuvaRing since updating the drug’s label in 2013 to include clearer blood clot risk information. That label change was itself partly driven by the litigation.

Here’s what has not changed: NuvaRing still contains etonogestrel, a third-generation progestin linked to elevated clotting risk. The product remains on the market with the same formulation.

• No new MDL filings as of 2026
• Organon now holds product liability exposure for current manufacturing
• The 2013 FDA label update remains the most recent safety action
• Generic versions of the etonogestrel/ethinyl estradiol vaginal ring exist

Women who are still using NuvaRing or its generic equivalents and experience clotting symptoms should document everything. Medical records from the time of injury are the backbone of any future claim.

NuvaRing Settlement Amounts

The NuvaRing settlement totaled $100 million, agreed upon in February 2014. This figure resolved approximately 3,800 lawsuits pending in the MDL and in state courts across the country.

Merck did not admit fault. The company stated publicly that it settled to avoid the cost and uncertainty of prolonged litigation. That’s standard language in mass tort resolutions, so it shouldn’t be read as evidence that claims lacked merit.

The $100 million figure sounds large. Divided by 3,800 claimants, the math looks very different. Individual payouts varied widely based on the severity of injury, strength of medical evidence, and whether the claimant had other risk factors for clotting.

Some women with catastrophic injuries like strokes or organ damage likely received more. Others with less severe outcomes received smaller amounts. Exact per-person figures were confidential under the settlement terms.

Key Takeaway: The NuvaRing MDL is closed, the $100 million settlement resolved roughly 3,800 claims, and Organon now carries product liability for current NuvaRing manufacturing.

NuvaRing Lawsuit Payout Per Person

The estimated NuvaRing lawsuit payout per person was approximately $26,000 on average, based on the $100 million fund divided among 3,800 claimants. But averages hide a wide range.

Individual payouts depended on a tiered system. Women who suffered permanent disability, organ damage, or lost a loved one received significantly more. Women with less severe injuries, such as a DVT that resolved with treatment, received less.

These figures are estimates based on reporting from legal analysts and mass tort attorneys. Merck did not publicly release the payout schedule.

Think of it like insurance claims after a natural disaster. Everyone draws from the same pool, but the person whose house was destroyed gets more than the person who lost a fence. The severity of your injury determined your share.

Attorney fees typically consumed 33% to 40% of each payout. So a claimant who received $26,000 before fees might have taken home $15,600 to $17,400 after legal costs. That’s a detail most lawsuit websites skip over.

Who Qualifies for the NuvaRing Lawsuit

Women who used NuvaRing and suffered a qualifying medical injury may be eligible to file a claim. The key requirement is a direct link between NuvaRing use and a documented health event.

To qualify, you generally need to prove three things:

• You used NuvaRing. Pharmacy records, prescription history, or medical chart notes can establish this.
• You suffered a qualifying injury. Blood clots, stroke, pulmonary embolism, heart attack, or death must be documented by medical professionals.
• The injury is connected to NuvaRing. A doctor or medical expert must confirm the device was a contributing cause.

Having other risk factors, like smoking, obesity, or a family history of clotting, doesn’t automatically disqualify you. It can complicate the case, but plenty of women with some risk factors still won claims in the original MDL.

The strongest cases involve women under 35, non-smokers, with no prior clotting history, who developed blood clots while actively using NuvaRing.

NuvaRing Blood Clot Lawsuit

The NuvaRing blood clot lawsuit was the core of the entire litigation. Blood clots were the most commonly alleged injury, and the science supporting the connection was strong enough to drive Merck toward settlement.

NuvaRing releases etonogestrel, a third-generation progestin. Multiple studies published between 2001 and 2012 showed that third-generation progestins carry a higher blood clot risk than older second-generation options.

A 2012 study published in the BMJ found that NuvaRing users had a 6.5 times higher risk of venous thromboembolism compared to women not using hormonal contraception. That’s the number that made headlines and powered the litigation.

• Deep vein thrombosis (DVT) was the most common injury
• Clots in the legs could travel to the lungs, causing pulmonary embolism
• Some clots reached the brain, causing stroke
• A smaller number of clots triggered heart attacks

Blood clots from NuvaRing don’t announce themselves with a warning label that says “this is the ring’s fault.” They show up as leg pain, swelling, chest tightness, or sudden shortness of breath. Many women didn’t connect the dots until a doctor or lawyer pointed out the link.

The lawsuits alleged Merck knew about the elevated clotting risk and failed to adequately warn patients and prescribing doctors. Internal documents produced during the litigation supported the argument that Merck downplayed the risk in marketing materials.

Key Takeaway: Blood clots were the central injury in NuvaRing lawsuits, and a 2012 BMJ study confirmed the ring carried a 6.5x higher clotting risk compared to no hormonal contraception.

NuvaRing Side Effects Lawsuit

The NuvaRing side effects lawsuit covers a broader category than blood clots alone. While clotting events drove the bulk of the litigation, other serious side effects were included in many claims.

Plaintiffs alleged the following side effects:

• Blood clots (deep vein thrombosis, superficial thrombosis)
• Pulmonary embolism (clot in the lungs)
• Stroke (ischemic stroke caused by clot reaching the brain)
• Heart attack (myocardial infarction)
• Gallbladder disease (requiring surgical removal)
• Death (from any of the above complications)

The legal theory behind these claims was “failure to warn.” Merck’s original NuvaRing labeling suggested the product’s clotting risk was comparable to oral birth control pills. Plaintiffs argued that was misleading because the ring delivers hormones differently, with constant low-dose absorption through vaginal tissue.

That delivery method creates different hormone levels in the blood compared to a daily pill. Scientists debated whether this altered pharmacokinetics contributed to higher clotting rates. The lawsuits forced that conversation into public view.

NuvaRing Class Action Lawsuit

The NuvaRing class action lawsuit is a common search term, but technically, the federal litigation was not a class action. It was a multidistrict litigation (MDL), which works differently.

In a class action, one lawsuit covers all affected people automatically. In an MDL, each plaintiff files their own individual case. Those cases get grouped together for pretrial proceedings to save time. Think of it as carpooling to the courthouse instead of everyone driving separately.

The NuvaRing MDL was assigned as MDL No. 1964 in the U.S. District Court for the Eastern District of Missouri. Judge Rodney W. Sippel oversaw the consolidated proceedings.

At its peak, the MDL contained over 1,500 federal cases. Additional cases were filed in state courts in New Jersey and other jurisdictions. The total across all courts reached approximately 3,800 by the time of settlement.

The MDL structure actually benefited plaintiffs in some ways. Because each case was individual, women with severe injuries weren’t forced to accept the same payout as women with minor ones. The per-person variability allowed the settlement to reflect real differences in harm.

NuvaRing Merck Settlement

The NuvaRing Merck settlement was finalized in 2014 for $100 million. Merck agreed to resolve roughly 3,800 pending claims without admitting liability or wrongdoing.

Merck’s decision to settle came after several developments pressured the company:

• Bellwether trials were being prepared. These are test cases in an MDL that signal how juries might react. Merck faced the prospect of losing even one trial, which could have set a damaging precedent.
• The 2012 BMJ study strengthened plaintiffs’ scientific argument.
• The FDA’s 2013 label update acknowledged elevated clotting risk, which undermined Merck’s defense that warnings were adequate.
• Internal documents surfaced during discovery showing Merck’s awareness of risk data.

The $100 million figure was considered modest by mass tort standards. For context, Bayer paid over $2 billion to settle Yaz/Yasmin birth control lawsuits involving similar blood clot claims. NuvaRing’s lower settlement reflected its smaller user base and fewer filed claims, not weaker science.

Merck’s stock barely moved on the announcement. For a company generating over $40 billion in annual revenue at the time, $100 million was a rounding error.

If you're curious, also see Recent Entertainment Lawsuit 2026: Full Settlement Guide

Key Takeaway: Merck settled for $100 million in 2014 without admitting fault, pressured by strong scientific evidence, FDA label changes, and the threat of bellwether trials.

How to File a NuvaRing Lawsuit

Filing a NuvaRing lawsuit in 2026 requires working with a personal injury or mass tort attorney who can evaluate whether your claim is still timely and viable. The process follows a standard personal injury framework.

Step-by-step filing process:

1. Gather your medical records. Pull every document showing NuvaRing was prescribed, filled, or noted in your chart. Get records from the hospital or clinic where your injury was treated.
2. Contact a product liability attorney. Look for firms with experience in pharmaceutical mass torts. Most offer free case evaluations and work on contingency, meaning you pay nothing upfront.
3. Medical review. Your attorney will have a medical expert review your records to determine whether your injury is causally linked to NuvaRing.
4. File the complaint. If the case has merit, your attorney drafts and files a complaint in the appropriate court. This could be state or federal court depending on your situation.
5. Discovery and negotiation. The defendant responds, evidence is exchanged, and settlement discussions begin. Most pharmaceutical cases settle before trial.

Since the MDL is closed, any new claim would be filed as an individual lawsuit. There’s no group to “join.” You file your own case with your own attorney.

NuvaRing Statute of Limitations

The NuvaRing statute of limitations varies by state and determines how long you have to file after your injury. Missing this deadline almost always kills your case, no matter how strong the evidence.

Most states give you two to three years from the date of injury to file a personal injury lawsuit. But here’s the wrinkle: many states apply a “discovery rule.” This means the clock starts when you knew, or should have known, that NuvaRing caused your injury, not necessarily when the injury happened.

Some states also have a statute of repose, which sets an absolute outer deadline regardless of when you discovered the harm. For example, if a state has a 10-year statute of repose for product liability, you cannot file more than 10 years after you last used the product, period.

For NuvaRing cases in 2026, the statute of limitations is the single biggest obstacle. Most injuries occurred between 2001 and 2014. Even with generous discovery rules, many claims are time-barred.

If your injury happened recently, meaning within the last two to three years, you may still have time. But you need to verify this with an attorney immediately.

Can You Still Sue for NuvaRing Injuries

Yes, you can potentially still sue for NuvaRing injuries in 2026, but only under specific circumstances. The window is narrow, and it depends on when your injury occurred and when you discovered the connection to NuvaRing.

You may still have a case if:

• Your blood clot, stroke, or other injury happened within the last two to three years
• You only recently learned that NuvaRing was the cause of an older injury
• Your state applies a discovery rule that delays the start of the limitations period
• You are a family member filing a wrongful death claim where the death was recent

You likely cannot sue if:

• Your injury occurred more than three years ago and you knew about the NuvaRing connection at the time
• Your state’s statute of repose has expired
• You already received a payout from the 2014 settlement (those claims included releases barring future suits)

Think of the statute of limitations like a parking meter. Once it expires, it doesn’t matter that you were legitimately parked there. The window closed, and nothing changes that except rare legal exceptions.

If you’re unsure, the only way to know for certain is a case evaluation by an attorney licensed in your state. This costs nothing at most mass tort firms, and it takes less than an hour.

Key Takeaway: New NuvaRing lawsuits are technically possible in 2026, but the statute of limitations has expired for most women whose injuries occurred during the peak usage years.

NuvaRing Stroke Lawsuit

NuvaRing stroke lawsuits involved some of the most devastating injuries in the entire litigation. Women who suffered ischemic strokes, caused by blood clots blocking blood flow to the brain, filed claims alleging NuvaRing was responsible.

Strokes caused by NuvaRing typically occurred in women under 40 with no prior stroke risk factors. That pattern is what made the cases so compelling. Young, otherwise healthy women don’t normally have strokes. When they do, doctors look for an external cause.

The mechanism is straightforward. NuvaRing’s hormones increase clotting tendency. A clot forms, travels through the bloodstream, and lodges in a cerebral artery. Brain tissue downstream of the blockage dies within minutes.

Stroke outcomes in NuvaRing cases included:

• Permanent paralysis on one side of the body
• Speech and language impairment
• Vision loss
• Cognitive decline
• Inability to work or live independently
• Death

Stroke cases received higher payouts in the settlement because the injuries were severe and often permanent. A woman who had a stroke at 28 and can no longer work has decades of lost earnings, ongoing medical costs, and profound quality-of-life losses.

These cases were among the strongest in the MDL. The combination of young age, no preexisting risk factors, and clear temporal connection to NuvaRing use made them difficult for Merck to defend.

NuvaRing and Pulmonary Embolism Claims

Pulmonary embolism, or PE, was one of the most serious injuries alleged in NuvaRing lawsuits. A PE occurs when a blood clot, usually from the legs, breaks loose and travels to the lungs.

Symptoms of pulmonary embolism include sudden shortness of breath, sharp chest pain, rapid heartbeat, and coughing up blood. It can be fatal within hours if the clot is large enough to block a major pulmonary artery.

In the NuvaRing litigation, PE cases were considered high-severity claims. Women who survived a pulmonary embolism often faced lasting lung damage, exercise intolerance, and the need for lifelong blood-thinning medication.

• DVT usually comes first. A clot forms in the deep veins of the leg.
• The clot breaks free. It enters the bloodstream and travels toward the heart and lungs.
• It lodges in a pulmonary artery. This blocks blood flow to part of the lung.
• Oxygen levels drop. The heart works harder to compensate, sometimes leading to cardiac arrest.

The connection between NuvaRing and PE is well-documented in medical literature. Etonogestrel, the progestin in NuvaRing, promotes clot formation. Once a DVT develops, the risk of PE follows.

Many women in the MDL didn’t realize their PE was connected to their birth control. They went to the emergency room thinking they were having a heart attack or panic attack, only to learn a blood clot had reached their lungs.

NuvaRing Death Lawsuits

NuvaRing death lawsuits were filed by families of women who died from blood clots, pulmonary embolism, or strokes allegedly caused by the contraceptive ring. These wrongful death claims represented the most tragic cases in the MDL.

Several highly publicized deaths drove media coverage and public awareness of NuvaRing risks. Young women in their 20s and 30s, seemingly healthy, died suddenly from clotting events while using the device.

Notable patterns in death cases:

• Victims were typically under 35
• Most had no known clotting disorders
• Deaths often occurred within the first year of NuvaRing use
• Cause of death was usually massive pulmonary embolism or stroke

Wrongful death cases carry a heavier emotional weight than injury cases. Juries tend to award larger verdicts when a young person dies from a preventable cause. That dynamic gave these cases significant settlement value.

Families who lost a loved one to a NuvaRing-related death and did not participate in the 2014 settlement may still have options, depending on when the death occurred and their state’s wrongful death statute of limitations.

Key Takeaway: NuvaRing stroke, pulmonary embolism, and death cases represented the most severe injuries in the litigation and received the highest payouts within the settlement structure.

Worth reading: Johnson & Johnson Lawsuit 2026: Updates and Payouts

NuvaRing Blood Clot Risk vs Other Birth Control

NuvaRing carries a higher blood clot risk than most other forms of hormonal birth control. Studies consistently show that third-generation progestins, like the etonogestrel in NuvaRing, increase venous thromboembolism risk more than older formulations.

The comparison matters because Merck’s original marketing suggested NuvaRing’s risk was similar to standard birth control pills. Lawsuits argued that claim was misleading.

A closely related topic: Unemployment Lawsuit This Week: 2026 Updates & Payouts

Sources: BMJ 2012, FDA safety communication 2013, European Medicines Agency review

The data shows NuvaRing’s clotting risk is roughly double that of older second-generation pills containing levonorgestrel. It’s comparable to the risk from desogestrel pills and the Ortho Evra patch.

Here’s a useful analogy: all cars have some crash risk. But if one model has twice the crash rate and the manufacturer markets it as “just as safe as every other car,” that’s a problem. That’s essentially what plaintiffs argued Merck did with NuvaRing.

The absolute numbers are still small. Most women who use NuvaRing will never develop a blood clot. But for the women who do, especially those who were never told about the elevated risk, the consequences can be devastating.

NuvaRing Recall History

NuvaRing has never been fully recalled from the U.S. market. The product remains available by prescription and is still manufactured by Organon & Co. However, there have been limited recalls related to manufacturing and packaging issues.

Notable NuvaRing recalls:

• 2008: A voluntary recall was issued for certain lots due to packaging concerns. Some rings were found outside their foil pouches, potentially reducing their effectiveness.
• 2010: Another limited recall addressed manufacturing deviations in specific batches.
• 2014: A recall involved rings that may not have contained the correct hormone levels.

None of these recalls were related to the blood clot risk that fueled the lawsuits. They addressed manufacturing quality issues, not the fundamental safety of the product’s hormonal formulation.

The FDA never required a full market withdrawal. Instead, the agency took the softer approach of mandating label updates. The 2013 label revision added stronger language about blood clot risks, particularly for women with additional risk factors like smoking or obesity.

Some consumer advocates argued that a full recall was warranted. The FDA disagreed, concluding that the benefits of NuvaRing outweighed its risks when patients were properly informed. Whether “properly informed” actually happened at the doctor’s office is another question entirely.

Key Takeaway: NuvaRing has never been fully recalled despite carrying a higher blood clot risk than many alternatives; the FDA opted for label changes rather than a market withdrawal.

Frequently Asked Questions

How much money can I get from a NuvaRing lawsuit?

The average payout from the 2014 settlement was roughly $26,000 per claimant before attorney fees.

Severe cases involving stroke or pulmonary embolism received significantly more, potentially $100,000 to $500,000.

Your payout depends on injury severity, medical documentation, and whether your claim is still timely.

Is there a NuvaRing lawsuit in 2026?

The original NuvaRing MDL is closed and the $100 million settlement was distributed years ago.

Individual lawsuits may still be filed in 2026 if the plaintiff’s statute of limitations has not expired.

No new mass litigation or MDL has been created as of early 2026.

What side effects qualify for a NuvaRing claim?

Qualifying injuries include deep vein thrombosis, pulmonary embolism, stroke, heart attack, and death.

These must be medically documented and linked to NuvaRing use by a healthcare professional.

Less severe side effects like headaches or mood changes generally do not support a lawsuit.

Has the NuvaRing statute of limitations expired?

For most women injured during NuvaRing’s peak usage years (2001 to 2014), the statute of limitations has expired.

Exceptions may apply if you recently discovered the connection between your injury and NuvaRing.

State discovery rules and statutes of repose vary, so a case evaluation is the only way to confirm.

Did Merck admit NuvaRing was dangerous?

No. Merck settled for $100 million in 2014 without admitting fault or liability.

The company maintained that NuvaRing was safe and effective when used as directed.

The FDA’s 2013 label update, however, acknowledged an elevated blood clot risk compared to older contraceptives.

The NuvaRing lawsuit shaped how pharmaceutical companies communicate birth control risks. If you used this device and suffered a serious injury, your options depend on timing and evidence.

Collect your medical records and prescription history now. Contact a product liability attorney for a free case evaluation to find out whether your claim can still move forward in 2026.

The clock is ticking. Don’t wait to find out where your state’s deadline falls.

See also: Asbestos Lawsuit Settlements in 2026: Payouts Guide

Something similar worth reading: J&J Lawsuit Settlement: 2026 Payouts and Updates

Before you go further, consider reading Shocking Automotive Lawsuit 2026: Who Qualifies for Payouts

Never Miss a Lawsuit Update

Mark Lawfold as a Preferred Source so you never miss a settlement deadline or new filing.